IMR Press / FBL / Special Issues / platelet-activating_factor

New Insights into Platelet- Activating Factor

Submission deadline: 30 May 2024
Special Issue Editor
  • Smaragdi Antonopoulou, PhD
    Department of Nutrition-Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece
    Interests: platelet-activating factor; lipids; inflammation; mediterranean diet; food industry by-products
Special Issue Information

Dear Colleagues,

More than 50 years have passed since the term PAF (Platelet-Activating Factor) was first coined by Benveniste, Henson, and Cochrane in 1972 to describe the activities of PAF that were known until then, namely platelet activation and aggregation. Its chemical structure was elucidated in 1979 as a glyceryl-ether lipid (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by Demopoulos, Pinckard, and Hanahan. PAF is now recognized as a primitive lipid mediator with several actions in almost all human systems, and has been implicated in various physiological and pathophysiological processes.

PAF is a potent inflammatory mediator that is implicated in a variety of conditions and chronic diseases, such as allergies, asthma, infections, cancer, renal diseases, cerebrovascular and central nervous system disorders, cardiovascular diseases and recently in COVID-19. In addition to its role in acute inflammation, PAF is also involved in cell signaling mechanisms for a number of physiological processes, including apoptosis, wound healing, reproduction and angiogenesis.

PAF exerts its actions mainly by binding to the its G-protein-coupled receptor (PAF-R) located on the plasma and nuclear membrane and expressed by a variety of cells and tissues. PAF-R also interacts with PAF-like oxidized phospholipids (Ox-PLs) and recognizes components of the bacterial wall, such as lipoteichoic acid and lipopolysaccharides. PAF action and metabolism can be modulated in different ways, such as by diet, lifestyle, and environmental factors. PAF has been a therapeutic target for many chronic diseases, and therefore, several natural and synthetic origin PAF antagonists have been studied across several disciplines.

This Special Issue aims to integrate current knowledge regarding the functions of PAF in an attempt to determine novel therapeutics that most likely target PAF in conjunction with various other inflammatory mediators.

Prof. Smaragdi Antonopoulou
Guest Editor

PAF and diet
oxidized phospholipids and plasmalogens in inflammation
the importance of PAF in angiogenesis
the role of PAF in immunopathology
PAF and cancer
PAF and CNS disorders
PAF and COVID-19
PAF and allergies
PAF and cardiovascular diseases
PAF and gut microbiota
PAF inhibitors
PAF as a therapeutic target
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Planned Paper (1 Paper)
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to IMR Press journals will subject to peer-review before acceptance

Re-assessing the role of Platelet Activating Factor and its inflammatory signaling and inhibitors in cancer and anti-cancer strategies

Alexandros Tsoupras, Theodora Adamantidi, Marios Finos, Athanassios Philippopoulos, Constantinos A. Demopoulos

Published Paper (1 Paper)
Back to top